FEUrea Calculator

What is FEUrea?

Fractional Excretion of Urea (FEUrea) is a calculated laboratory value used to help determine the underlying cause of acute kidney injury (AKI). It measures the percentage of urea filtered by the kidneys that ultimately appears in the urine. By comparing the ratio of urea clearance to creatinine clearance, FEUrea provides insight into whether the kidneys are responding normally to reduced blood flow (prerenal azotemia) or whether the renal tubules themselves are damaged (intrinsic renal disease).

FEUrea was introduced as a clinical tool to address a significant limitation of the more commonly known Fractional Excretion of Sodium (FENa). While FENa is an excellent marker for distinguishing prerenal from intrinsic causes of AKI under normal circumstances, its accuracy is severely compromised in patients receiving diuretics. Diuretics increase sodium excretion regardless of the underlying renal pathology, rendering FENa unreliable. FEUrea, on the other hand, is not significantly affected by diuretic use because urea reabsorption in the proximal tubule is driven by passive concentration gradients and is coupled to water reabsorption rather than active sodium transport.

In prerenal azotemia, the kidneys are structurally intact but underperfused. The tubules respond by avidly reabsorbing both sodium and urea to conserve volume, resulting in a low FEUrea (below 35%). In intrinsic renal disease such as acute tubular necrosis (ATN), the damaged tubules lose their ability to concentrate urine and reabsorb solutes efficiently, leading to a higher FEUrea (35% or above). This distinction is clinically important because prerenal AKI is typically reversible with fluid resuscitation, while intrinsic renal disease may require different management strategies.

FEUrea is particularly valuable in the intensive care unit (ICU) and emergency department settings where patients commonly receive loop diuretics such as furosemide. In these environments, distinguishing between prerenal and intrinsic causes of rising creatinine has direct implications for treatment decisions, including fluid management, diuretic adjustment, and the need for nephrology consultation or renal replacement therapy.

FEUrea Formula

The formula calculates the fractional excretion by comparing the urea clearance to the creatinine clearance. Each variable in the equation plays a specific role:

• Urine Urea (U_Urea): The concentration of urea nitrogen measured in a spot urine sample, expressed in mg/dL. Higher values indicate greater urea excretion by the kidneys.
• Serum/Blood Urea Nitrogen (BUN or S_Urea): The concentration of urea nitrogen in the blood, expressed in mg/dL. This reflects the balance between hepatic urea production and renal excretion.
• Urine Creatinine (U_Cr): The concentration of creatinine in a spot urine sample, expressed in mg/dL. Creatinine concentration in urine is typically much higher than in serum due to water reabsorption.
• Serum Creatinine (S_Cr): The concentration of creatinine in the blood, expressed in mg/dL. Elevated serum creatinine is a hallmark of impaired kidney function.

The formula can also be expressed as a ratio of clearances:

Where Urea Clearance = (U_Urea × V) ÷ S_Urea and Creatinine Clearance = (U_Cr × V) ÷ S_Cr. The urine volume (V) cancels out, which is why a timed urine collection is not required — a spot urine sample is sufficient.

FEUrea Interpretation

The primary clinical cutoff for FEUrea is 35%. This threshold is used to classify the likely cause of acute kidney injury:

FEUrea Value	Classification	Interpretation	Common Causes
< 35%	Prerenal	Kidney underperfusion with intact tubular function; urea is avidly reabsorbed	Dehydration, heart failure, hemorrhage, sepsis (early), hepatorenal syndrome
≥ 35%	Intrinsic Renal	Tubular damage with impaired urea reabsorption	Acute tubular necrosis (ATN), interstitial nephritis, nephrotoxins, glomerulonephritis

It is important to understand that the 35% cutoff is a guideline rather than an absolute dividing line. Clinical context, patient history, medication use, and trends in laboratory values should all be considered alongside the FEUrea result. Some studies have reported slightly different optimal cutoffs ranging from 30% to 40%, but 35% remains the most widely accepted and cited threshold in clinical practice.

FEUrea values near the cutoff (e.g., 30–40%) should be interpreted with caution and in conjunction with other clinical and laboratory data. Serial measurements may be more informative than a single value, as they can reveal trends in renal function over time.

FEUrea vs FENa

Both FEUrea and FENa (Fractional Excretion of Sodium) are used to differentiate prerenal from intrinsic renal causes of AKI, but they have important differences that determine when each should be used:

Feature	FENa	FEUrea
Prerenal cutoff	< 1%	< 35%
Intrinsic renal cutoff	> 2%	≥ 35%
Affected by diuretics	Yes — unreliable	No — remains reliable
Mechanism	Sodium actively reabsorbed in proximal tubule	Urea passively reabsorbed following water
Best used when	Patient is NOT on diuretics	Patient IS on diuretics or FENa is equivocal
Sensitivity for prerenal AKI	High (when no diuretics)	High (regardless of diuretics)
Limitations	Falsely elevated with diuretics, contrast agents, bicarbonate infusion	May be affected by high protein diet, GI bleeding, severe liver disease

The key advantage of FEUrea is its reliability in patients receiving diuretic therapy. Loop diuretics (such as furosemide) and thiazide diuretics directly inhibit sodium reabsorption in the renal tubules, causing FENa to rise above 1% even in patients with prerenal azotemia. This can lead to a false classification of intrinsic renal disease, potentially resulting in under-resuscitation. FEUrea avoids this pitfall because urea transport is not directly affected by these medications.

A landmark study by Carvounis et al. (2002) demonstrated that FEUrea had a sensitivity of 85% and specificity of 92% for identifying prerenal azotemia in patients receiving diuretics, compared to only 48% sensitivity for FENa in the same population. This established FEUrea as the preferred diagnostic tool when diuretic use is a confounding factor.

In clinical practice, the recommended approach is to use FENa as the first-line test when the patient is not receiving diuretics, and to switch to FEUrea when diuretics have been administered or when FENa results are ambiguous (between 1% and 2%). Some clinicians calculate both values simultaneously for a more comprehensive assessment.

Acute Kidney Injury (AKI)

Acute Kidney Injury (AKI), formerly known as acute renal failure, is defined as a sudden decline in kidney function that develops over hours to days. It is characterized by a rise in serum creatinine, a decrease in urine output, or both. AKI is classified using the KDIGO (Kidney Disease: Improving Global Outcomes) staging criteria:

Stage	Serum Creatinine Criteria	Urine Output Criteria
Stage 1	1.5–1.9 times baseline OR ≥ 0.3 mg/dL increase within 48 hours	< 0.5 mL/kg/h for 6–12 hours
Stage 2	2.0–2.9 times baseline	< 0.5 mL/kg/h for ≥ 12 hours
Stage 3	≥ 3.0 times baseline OR creatinine ≥ 4.0 mg/dL OR initiation of renal replacement therapy	< 0.3 mL/kg/h for ≥ 24 hours OR anuria for ≥ 12 hours

AKI is broadly classified into three categories based on the location of the underlying problem:

• Prerenal AKI (approximately 55–60% of cases): Caused by decreased blood flow to the kidneys. The renal parenchyma itself is structurally normal, but inadequate perfusion leads to reduced glomerular filtration. Common causes include dehydration, hemorrhage, congestive heart failure, sepsis (early stages), severe burns, and the use of NSAIDs or ACE inhibitors/ARBs that alter renal hemodynamics. Prerenal AKI is typically reversible with restoration of adequate renal perfusion.
• Intrinsic Renal AKI (approximately 35–40% of cases): Caused by direct damage to the kidney parenchyma, including the glomeruli, tubules, interstitium, or renal vasculature. Acute tubular necrosis (ATN) is the most common form, resulting from prolonged ischemia (often progression from prerenal AKI) or nephrotoxic insults (aminoglycosides, contrast dye, cisplatin, myoglobin from rhabdomyolysis). Other causes include acute interstitial nephritis (drug-induced allergic reaction), glomerulonephritis, and thrombotic microangiopathy.
• Postrenal AKI (approximately 5% of cases): Caused by obstruction of urine flow anywhere from the renal pelvis to the urethra. Bilateral obstruction (or unilateral in a solitary kidney) is required to cause significant AKI. Common causes include benign prostatic hyperplasia (BPH), kidney stones, tumors compressing the ureters, and urethral strictures. Diagnosis is typically made with renal ultrasound showing hydronephrosis.

Determining the type of AKI is crucial because the treatment approach differs significantly. FEUrea is one of the laboratory tools used to distinguish prerenal from intrinsic renal causes, which together account for over 90% of AKI cases.

Urea as a Clinical Parameter

Urea is the primary end product of protein metabolism in humans. It is produced in the liver through the urea cycle, where ammonia (a toxic byproduct of amino acid deamination) is converted to the much less toxic urea molecule. From the liver, urea enters the bloodstream and is eventually filtered by the kidneys for excretion in urine.

The concentration of urea in the blood is commonly measured as Blood Urea Nitrogen (BUN) in the United States, or simply as serum urea in many other countries. Normal BUN values range from approximately 7 to 20 mg/dL (2.5 to 7.1 mmol/L). BUN can be elevated due to renal failure, but also from non-renal causes including high protein intake, gastrointestinal bleeding (where blood proteins are digested and absorbed), catabolic states (trauma, burns, sepsis), dehydration, and certain medications such as corticosteroids.

In the kidney, urea is freely filtered at the glomerulus. Approximately 40–60% of the filtered urea is passively reabsorbed in the proximal tubule, driven by concentration gradients established by water reabsorption. In the medullary collecting duct, urea transporters (UT-A1 and UT-A3) facilitate additional urea reabsorption, which is regulated by antidiuretic hormone (ADH/vasopressin). This reabsorption contributes to the medullary concentration gradient essential for the kidney's ability to concentrate urine.

In prerenal states, increased water and sodium reabsorption in the proximal tubule creates a steeper concentration gradient that enhances passive urea reabsorption. Additionally, elevated ADH levels (a normal response to hypovolemia) further increase urea reabsorption in the collecting duct. Both mechanisms lower urine urea concentration and reduce FEUrea. This physiological response explains why FEUrea is low in prerenal AKI and forms the basis for using this calculation as a diagnostic tool.

Creatinine as a Clinical Parameter

Creatinine is a waste product generated from the normal breakdown of creatine and phosphocreatine in skeletal muscle. It is produced at a relatively constant rate determined primarily by an individual's muscle mass, making it a useful marker of kidney function. Normal serum creatinine values are approximately 0.7 to 1.2 mg/dL for adult males and 0.5 to 1.0 mg/dL for adult females, though these ranges can vary by laboratory and assay method.

Creatinine is freely filtered at the glomerulus and is neither significantly reabsorbed nor metabolized by the renal tubules. A small amount (approximately 10–15%) is secreted by the proximal tubular cells into the tubular lumen. Because of these properties, creatinine clearance closely approximates the glomerular filtration rate (GFR), which is the gold standard measure of kidney function.

When kidney function declines, the GFR decreases and serum creatinine rises because the kidneys can no longer filter it as efficiently. However, serum creatinine is an imperfect marker: it may not rise until GFR has fallen by 50% or more (a phenomenon called the "creatinine-blind range"), it lags behind actual GFR changes by 24–48 hours, and it is influenced by factors other than kidney function such as muscle mass, diet (cooked meat intake), and certain medications (e.g., trimethoprim, cimetidine) that inhibit tubular creatinine secretion without affecting GFR.

In the FEUrea formula, creatinine serves as a reference marker for glomerular filtration. By comparing the renal handling of urea (which is variably reabsorbed) to creatinine (which is minimally reabsorbed), the formula normalizes urea excretion to the overall filtration rate, providing a measure of tubular urea handling independent of urine flow rate.

How to Use This Calculator

Follow these steps to calculate the Fractional Excretion of Urea using this tool:

1. Obtain laboratory values: You will need four values from a concurrent blood draw and spot urine sample. The blood test provides serum creatinine and BUN (blood urea nitrogen). The urine test provides urine creatinine and urine urea. Ideally, the blood and urine samples should be collected at approximately the same time to ensure accuracy.
2. Enter Urine Urea: Input the urine urea concentration in mg/dL in the first field. The default value is 300 mg/dL. Typical urine urea concentrations range from 100 to 1500 mg/dL depending on hydration status and protein intake.
3. Enter Serum/Blood Urea (BUN): Input the blood urea nitrogen concentration in mg/dL. The default value is 40 mg/dL. In AKI, BUN is typically elevated above the normal range of 7–20 mg/dL.
4. Enter Urine Creatinine: Input the urine creatinine concentration in mg/dL. The default value is 80 mg/dL. Urine creatinine is typically much higher than serum creatinine, with values commonly between 20 and 300 mg/dL.
5. Enter Serum Creatinine: Input the serum creatinine concentration in mg/dL. The default value is 2.0 mg/dL. In AKI, this value is elevated above the normal range.
6. Click "Calculate FEUrea": The calculator will compute the fractional excretion of urea using the standard formula and display the result as a percentage along with the clinical interpretation.
7. Review the results: The result panel shows the FEUrea percentage, classification (prerenal or intrinsic renal), clinical significance, and a note comparing FEUrea to FENa. Use the result in conjunction with the patient's clinical picture to guide further management.

Frequently Asked Questions

What is a normal FEUrea value?

In healthy individuals with normal kidney function, FEUrea typically ranges from 50% to 65%, meaning the kidneys excrete roughly half to two-thirds of the filtered urea. However, FEUrea is primarily a diagnostic tool used in the context of AKI rather than a routine screening test. In the setting of AKI, a FEUrea below 35% suggests prerenal etiology (the kidneys are avidly reabsorbing urea due to volume depletion or reduced perfusion), while a value of 35% or above suggests intrinsic renal damage where the tubules have lost their ability to reabsorb urea normally.

Why should I use FEUrea instead of FENa?

FEUrea should be used instead of FENa when the patient is receiving diuretic therapy (loop diuretics, thiazides, or other natriuretic agents). Diuretics directly inhibit sodium reabsorption in the renal tubules, causing FENa to increase above the prerenal threshold of 1% even when the underlying pathology is prerenal. This leads to misclassification. FEUrea is not affected by diuretics because urea reabsorption occurs passively and is driven by water movement rather than active sodium transport. Even when the patient is not on diuretics, some clinicians prefer to calculate both FENa and FEUrea for a more comprehensive assessment, particularly when FENa falls in the indeterminate zone between 1% and 2%.

What is acute kidney injury (AKI)?

Acute kidney injury is a rapid deterioration of kidney function occurring over hours to days. It is defined by the KDIGO criteria as an increase in serum creatinine of 0.3 mg/dL or more within 48 hours, an increase to 1.5 times baseline or more within 7 days, or a urine output of less than 0.5 mL/kg/h for 6 hours. AKI can range from mild dysfunction to complete kidney failure requiring dialysis. It is classified into prerenal (reduced blood flow to kidneys), intrinsic renal (direct kidney damage), and postrenal (urinary obstruction) categories. AKI is common in hospitalized patients, particularly in the ICU, and is associated with significant morbidity and mortality. Early identification and treatment of the underlying cause are essential for optimal outcomes.

When should the FEUrea test be ordered?

FEUrea should be ordered when a patient presents with acute kidney injury and the clinical team needs to distinguish between prerenal and intrinsic renal causes. It is especially indicated in the following scenarios: the patient is currently receiving or has recently received diuretics, the FENa result is equivocal (between 1% and 2%), or there is clinical uncertainty about the etiology of AKI despite other diagnostic data. The test requires only a spot urine sample and a blood draw, making it readily available in most clinical settings. It is important to note that FEUrea should be interpreted in the context of the complete clinical picture, including patient history, physical examination findings, urine microscopy, and imaging studies. No single laboratory test should be used in isolation to determine the cause of AKI.

Are there situations where FEUrea may be unreliable?

While FEUrea is more reliable than FENa in patients on diuretics, there are situations where its accuracy may be reduced. High protein diets or enteral/parenteral nutrition can increase urea production and alter FEUrea values. Upper gastrointestinal bleeding leads to absorption of blood proteins, increasing BUN disproportionately and potentially lowering FEUrea. Severe liver disease impairs urea synthesis, which may affect the reliability of urea-based calculations. Chronic kidney disease with pre-existing tubular dysfunction can also complicate interpretation. Additionally, in very early AKI (within the first few hours), both FENa and FEUrea may not yet reflect the underlying pathology. Despite these limitations, FEUrea remains a valuable and widely used clinical tool when interpreted alongside other clinical data.